Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
2 participants
INTERVENTIONAL
2020-02-15
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fase I Clinical Trial on NK Cells for COVID-19
NCT04634370
A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19
NCT04324996
NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors
NCT05528341
Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I
NCT03882840
NK Cells Infusion for Advanced Malignancies
NCT03619954
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NK Cells Treatment Group
Conventional treatment plus NK cells. Participants will receive conventional treatment plus twice a week of NK cells (0.1-2\*10E7 NK cells/kg body weight).
NK Cells
twice a week of NK cells (0.1-2\*10E7 cells/kg body weight)
Conventional Control Group
Participants will only receive conventional treatment.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NK Cells
twice a week of NK cells (0.1-2\*10E7 cells/kg body weight)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 2\. Pneumonia that is judged by chest radiograph or computed tomography
* 3\. Laboratory confirmation of NCP infection by reverse-transcription polymerase chain reaction(RT-PCR) from any diagnostic sampling source
Exclusion Criteria
* 2\. Known HIV, HBV or HCV infection
* 3\. Patients with malignant tumor, other serious systemic diseases and psychosis
* 4\. Patients who are participating in other clinical trials
* 5\. Inability to provide informed consent or to comply with test requirements
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
First Affiliated Hospital of Xinjiang Medical University
OTHER
Xinxiang medical university
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NK-COVID19
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.